Dr. Maria J. Valente, MD

Dr. Valente practices at Cancer Specialists of North Florida in Jacksonville, Florida.

Dr. Valente's NPI, 1902889959, was assigned on November 23, 2005. Dr. Valente graduated from University Of Michigan Medical School in 1997. Dr. Valente holds Florida license ME79666.

Dr. Valente's primary practice is Cancer Specialists of North Florida, at 7015 A C Skinner Pkwy, Jacksonville, FL 32256 in Duval County. The practice phone is (904) 363-2113.

Dr. Valente's primary practice is Cancer Specialists of North Florida in Jacksonville, Florida. Dr. Valente is also affiliated with Baptist Medical Center Jacksonville. The medical group on file is Cancer Specialists of North Florida. Dmand AI also links Dr. Valente to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Valente practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Valente's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Valente is board certified in medical oncology by the American Board of Internal Medicine. Dr. Valente is licensed in Florida.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances, immune deficiency disease and lung cancer among the conditions Dr. Valente treats.

CMS data shows 10,676 Medicare services from Dr. Valente across 23 procedure codes in 2024, for 362 Medicare patients. Medicare paid $203,310 for them.

CMS counts 362 Medicare patients who saw Dr. Valente in 2024. The largest group is 65 to 74, with 151 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Valente's median patient age at 68, with 70% women.

In 2024, Dr. Valente wrote 641 Medicare Part D claims for 133 patients. 71% of them were for generic drugs. CMS names the drug for 405 of them, across 17 drugs with 11 or more claims each, at $572,647 in total drug cost. In 2023, CMS named 500 claims across 17 drugs.

Dr. Valente accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Valente as offering telehealth.

Dmand AI links 15 papers to Dr. Valente, published from 2010 to 2024. 2011 was the busiest year, with 2. The most frequent topics are Cells, Cultured, Hepatocytes and Adenosine Triphosphate. Dr. Valente has published most often in Arch Toxicol. Dr. Valente's most frequent co-authors are Angela Dispenzieri, MD, Morie A. Gertz, MD and Martha Q. Lacy, MD.

CMS Open Payments shows 129 general payments to Dr. Valente from 53 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Novartis Pharmaceuticals Corporation paid the most, $233.

Dmand AI lists 1 award for Dr. Valente, most recently CMS Stage 1 EHR in 2013.

Dr. Valente graduated from University Of Michigan Medical School in 1997. Dr. Valente is a member of ASCO.

Dr. Valente is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.